The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 1.50 (17.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.25
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options to Director

25 May 2018 07:00

RNS Number : 2598P
Norman Broadbent PLC
25 May 2018
 

Norman Broadbent plc

("Norman Broadbent" or "the Company")

Grant of Options to Director

Norman Broadbent (AIM: NBB) - a leading Professional Services firm specifically focussing on Leadership Acquisition & Advisory Services (Board & Leadership Search, Senior Interim Management, Research & Insight, Leadership Consulting & Assessment, and executive level Recruitment Solutions) announces that on 24 May 2018 the Company's Remuneration Committee recommended and approved the grant of 1,054,191 options (the "Options") to executive director Will Gerrand the Group's CFO/COO who joined the group on 5 October 2017.

The options, which are being granted under the rules of the Company's Enterprise Management Incentive Share Option Scheme 2007 (the "Scheme"), are exercisable at 13.5p per ordinary share. This represents a c.25.6% premium to the mid-market price at market close on 24 May 2018 of 10.75p.

The pricing and conditions attaching to the Options are the same as those share options issued to other executive directors as announced on 6 June 2016 in order to align the option incentive across the executive team.

The Options granted will vest in two equal tranches and are subject to different tiered vesting criteria related to: (i) share price or corporate performance; and (ii) time duration. Once vested, the options can be exercised at any time up to the seventh anniversary of the date of grant, being 24 May 2025.

50 per cent. of the options granted vest subject to certain average share prices being achieved prior to 31 July 2020 and the remaining 50 per cent. vest subject to certain audited EBITDA figures being achieved for a financial year prior to 31 December 2019. EBITDA in this context is defined as earnings before interest, tax, depreciation and amortisation, excluding any non-recurring exceptional items as determined reasonable by the Remuneration Committee. Both tranches of options vest equally over three years from the date of issue, with the first such vesting date on the first anniversary of issue being 24 May 2019 and are subject to Will Gerrand's continued employment.

The tiered average three month share prices which must be achieved for the vesting of the first tranche range between 22p and 70p per ordinary share. In addition, the audited EBITDA which must be achieved for the second tranche of options to vest ranges between approximately £600,000 and approximately £2 million. In any year where the EBITDA number achieved is less than 100 per cent. but greater than 80 per cent. of the relevant target, the number of options available for vesting would be adjusted pro rata.

The following table sets out the details of the options granted to Will Gerrand

Share Price Vesting Options

EBITDA Vesting Options

Total number of options granted

Total number of options held

Percentage of existing issued shares under option

Percentage of the fully diluted share capital*

527,095

527,096

1,054,191

1,054,191

1.96%

1.82%

* assuming that no further ordinary shares are issued by the Company between the date of this announcement and the exercise of the options.

Following the issue of the options pursuant to the Scheme as detailed above, there are options outstanding over 4,152,702 ordinary shares, equivalent to 7.16 per cent. of the fully diluted share capital of the Company as at the date of this announcement, which are exercisable at exercise prices ranging from 13.5p to 65.5p per share. At the date of this announcement the Company has 53,885,570 ordinary voting shares in issue.

 The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Will Gerrand

2

Reason for the notification

a)

Position/status

CFO / COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Norman Broadbent Plc

b)

LEI

213800E5YN5TA934XA23

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1p each

 

GB00B3VF4Y66

b)

Nature of the transaction

Grant of share options

c)

Price(s) and volume(s)

 

 

Price:

Volume:

13.5p

1,054,191

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

24 May 2018

f)

Place of the transaction

London Stock Exchange, AIM

For further information, please contact:

Norman Broadbent plcMike Brennan / Will Gerrand

020 7484 0000

 

WH Ireland LimitedAdrian Hadden / Jessica Cave / Alex Bond

 

020 7220 1666

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPGUGAAUPRGQC
Date   Source Headline
20th May 20225:49 pmRNSIssue of Convertible Loan Notes
11th May 20224:16 pmRNSDirector resignation
18th Mar 20227:00 amRNSGrant of Options to Directors and Employees
2nd Mar 20227:00 amRNSFY2021 Trading Update
7th Feb 20227:00 amRNSBoard Changes
7th Dec 20213:50 pmRNSHolding(s) in Company
6th Dec 202110:18 amRNSSubscription
2nd Dec 20217:00 amRNSHolding(s) in Company
12th Nov 20212:30 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSAppointment of Group Managing Director
27th Sep 20217:02 amRNSSubscription Results and PDMR Dealing
27th Sep 20217:00 amRNSInterim Results for Six Months Ended 30 June 2021
12th Aug 20217:00 amRNSBoard Changes
12th Jul 20217:00 amRNSBoard Changes
25th Jun 202112:30 pmRNSResult of AGM
15th Jun 20217:00 amRNSAppointment of Executive Chairman
24th May 20217:00 amRNSFinal Results and Annual Accounts
13th May 202111:59 amRNSHolding(s) in Company
12th May 202112:17 pmRNSHolding(s) in Company
12th May 20219:39 amRNSHolding(s) in Company
19th Apr 202111:59 amRNSNotice of Results
19th Apr 202111:53 amRNSHolding(s) in Company
25th Jan 20217:00 amRNSFY2020 Trading Update
26th Nov 20207:00 amRNSFunding Update
23rd Nov 20204:54 pmRNSHolding(s) in Company
21st Oct 20201:45 pmRNSAppointments - Group Managing Director & Others
16th Oct 20201:00 pmRNSDirector/PDMR Shareholding & Concert Party Update
5th Oct 20203:01 pmRNSIssue of Equity
5th Oct 20207:00 amRNSAcquisition of minority interest in NBIMv
28th Sep 20207:00 amRNSInterim Results
27th Aug 202010:40 amRNSDirectorate Change
24th Aug 202010:59 amRNSDirector/PDMR Shareholding
28th Jul 202010:18 amRNSResult of AGM and Appointment of Chair
28th Jul 20207:00 amRNSAGM Statement and Trading Update
16th Jul 202010:35 amRNSHolding(s) in Company
29th Jun 20207:00 amRNSFinal Results and Annual Accounts
26th May 202011:32 amRNSDirector/PDMR Shareholding
18th May 202012:33 pmRNSDirector/PDMR Shareholding
18th May 20207:00 amRNSTrading Update
11th Mar 202012:00 pmRNSAppointment of CFO & COO
9th Mar 20207:00 amRNSChange of address
3rd Mar 20207:00 amRNSExpansion driven by increased client demand
28th Feb 20207:00 amRNSUpdate: Chief Financial Officer Succession
24th Jan 20207:00 amRNSTrading Update
10th Dec 20197:00 amRNSNorman Broadbent Group partners with UN Women UK
26th Sep 20197:00 amRNSInterim Results for six months ended 30 June 2019
9th Sep 20197:00 amRNSNew and Enhanced Working Capital Facility
23rd Aug 201911:31 amRNSHolding(s) in Company
23rd Aug 201910:51 amRNSShareholder Update and Director/PDMR Shareholding
6th Aug 20194:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.